{"links":{"feed":"https://www.erudio.com/reports/equuleus-nct01998971/feed.json","html":"https://www.erudio.com/reports/equuleus-nct01998971","json":"https://www.erudio.com/reports/equuleus-nct01998971.json","markdown":"https://www.erudio.com/reports/equuleus-nct01998971.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"equuleus-nct01998971"}},"request":"https://www.erudio.com/contact?report=equuleus-nct01998971"},"offer":{"cited_clinicians":7,"cited_commentary_sources":9,"verified_hcp_statements":244,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":7},"for_sale":true,"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"equuleus-nct01998971"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=equuleus-nct01998971","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/equuleus-nct01998971","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_line":"Standard · 244 verified statements · 93 from 7 confirmed clinicians","size_rule":"Standard: 151–300 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-18T17:09:40.120530Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":19,"no_commentary_found":1},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Number of participants affected by dose-limiting toxicities"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":4,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":2,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":2,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":3,"title":"Access-dependent regimen use"},{"claim_count":7,"coverage":"discussed","id":"A2","source_count":1,"title":"DREAMM-7 as an alternative-treatment discussion involving D-Vd"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":3,"title":"Maintenance component selection after contemporary frontline therapy"},{"claim_count":17,"coverage":"discussed","id":"A4","source_count":2,"title":"PERSEUS and AURIGA maintenance interpretation and prior CD38 exposure"},{"claim_count":26,"coverage":"discussed","id":"A5","source_count":4,"title":"MRD-informed decisions, treatment duration and treatment-free intervals"},{"claim_count":13,"coverage":"discussed","id":"A6","source_count":2,"title":"Transplantation after quadruplet induction and selective deferral"},{"claim_count":24,"coverage":"discussed","id":"A7","source_count":4,"title":"Contemporary frontline quadruplet rationale and implementation"},{"claim_count":22,"coverage":"discussed","id":"A8","source_count":3,"title":"Fitness, cytogenetic work-up and attenuated treatment in older patients"},{"claim_count":9,"coverage":"discussed","id":"A9","source_count":2,"title":"French frailty study and dexamethasone minimization"},{"claim_count":18,"coverage":"discussed","id":"A10","source_count":2,"title":"Proteasome-inhibitor choice, neuropathy and high-risk treatment intensity"},{"claim_count":6,"coverage":"discussed","id":"A11","source_count":1,"title":"Renal impairment and induction sequencing"},{"claim_count":14,"coverage":"discussed","id":"A12","source_count":3,"title":"Antibody selection, formulation and patient experience"},{"claim_count":17,"coverage":"discussed","id":"A13","source_count":2,"title":"Preparation, preventive care and patient support for combination treatment"}],"counts":{"beyond_population_findings":11,"beyond_population_statements":162,"cited_clinicians":7,"cited_clinicians_by_role":{"physician":4,"physician, Medical oncology":3},"cited_physicians":7,"cited_sources":15,"claims_by_expression_type":{"comparison":23,"experience":23,"interpretation":57,"opinion":66,"primary_context":17,"question":19,"restatement":20,"uncertainty":14,"unspecified":5},"claims_by_kind":{"interpretation":3,"objective_result":4,"protocol_statement":1,"publication_statement":59,"source_observation":177},"clinician_statements":93,"evidence_units":139,"findings":15,"organisational_accounts":4,"people_cited":9,"people_identity_verified":7,"people_total":9,"screened_sources":34,"verified_claims":244},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":5,"views":2},"limitations":3,"links":{"context":1,"support":9},"ma_question":true,"named_voices":1,"passages":6,"sources":4,"sources_by_kind":{"commentary":2,"publication":2}},"title":"Weekly KdD70: why a clinician welcomes the dosing option","title_holders":{"cited_claim_ids":["claim-6264941920838594f57f"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"9 statements from 1 speaker in 4 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F3","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":2},"limitations":2,"links":{"context":1,"support":3},"ma_question":true,"named_voices":1,"passages":4,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Anti-CD38–pomalidomide triplets: a clinician weighs prior lines and refractory status","title_holders":{"cited_claim_ids":["claim-0f70223e564a753574fb"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"3 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F4","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":1,"links":{"context":1,"support":1},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"D-Kd: a clinician welcomes approval but hopes for future regional access","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-24b929c7334bc85c483c"],"clause":"hope for future regional access","holders":1},"cited_claim_ids":["claim-24b929c7334bc85c483c"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “hope for future regional access”"},{"cited_clinicians":0,"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":1,"views":2},"limitations":3,"links":{"context":2,"support":8},"ma_question":true,"named_voices":1,"passages":5,"sources":1,"sources_by_kind":{"media":1}},"title":"DREAMM-7: how a speaker weighs potential benefit against vision risks","title_holders":{"cited_claim_ids":["claim-8cc69bb016eb6c0f5075","claim-5ac02231c25377d747e1","claim-96f7a04e51ccbcdcbe9a","claim-22763d8f7d2dbb44dd77"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"7 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":1,"id":"F5","population":"beyond","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":2},"limitations":2,"links":{"context":2,"support":3},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Single-drug maintenance: a clinician favors daratumumab over lenalidomide","title_holders":{"cited_claim_ids":["claim-772c039a80708be7bec3"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"3 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F6","population":"beyond","structure":{"claims":16,"claims_by_group":{"comparisons":1,"experience":0,"questions":6,"restated":4,"views":5},"limitations":4,"links":{"context":3,"support":18},"ma_question":true,"named_voices":1,"passages":10,"sources":2,"sources_by_kind":{"media":2}},"title":"CD38 maintenance: how a clinician weighs CD38-naïve data against post-quadruplet gaps","title_holders":{"cited_claim_ids":["claim-962753680fd3bd3d121a","claim-2a3f60cffcbe509b722c","claim-6e0b156033986a9b3abc","claim-996ef061fdface33af30","claim-1837a94001c222a6af67","claim-6449eecb19c7027cb0bd","claim-08f0968412b357ca0ef2","claim-f63b89960ff407d1d512","claim-366cf6121355dc034e4b","claim-a67d1c8f685f7ad9a221","claim-21d04c667b3451da2b4c","claim-29dbd6d4a623f0ec2a93"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"16 statements from 1 speaker in 2 sources, all podcasts or videos","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":4,"id":"F7","population":"beyond","structure":{"claims":26,"claims_by_group":{"comparisons":1,"experience":4,"questions":8,"restated":5,"views":8},"limitations":5,"links":{"context":1,"support":29},"ma_question":true,"named_voices":4,"passages":16,"sources":4,"sources_by_kind":{"media":4}},"title":"MRD-informed treatment reduction: where clinicians split on whether and when to stop","title_holders":{"cited_claim_ids":["claim-08cc91e3661abb4733f7","claim-7b62c8732313b719eab6","claim-4ac61f5efe7bb34db965","claim-c247da03a258e48915ba","claim-603f0e998a28189ee7a8","claim-2995cd9e0691d4f08ef4","claim-bc9d6665e67413060cbc","claim-32fcde4e7a780b2cfc61","claim-602cc4d3a73c6933044e","claim-c63c877d3f08b14936b3","claim-c26df25d230b32bca604"],"clinicians":true,"holders":3,"sides":[{"cited_claim_ids":["claim-08cc91e3661abb4733f7","claim-7b62c8732313b719eab6","claim-4ac61f5efe7bb34db965","claim-c247da03a258e48915ba","claim-603f0e998a28189ee7a8"],"holders":2},{"cited_claim_ids":["claim-2995cd9e0691d4f08ef4","claim-bc9d6665e67413060cbc","claim-32fcde4e7a780b2cfc61","claim-7b62c8732313b719eab6","claim-602cc4d3a73c6933044e","claim-4ac61f5efe7bb34db965","claim-c63c877d3f08b14936b3","claim-c26df25d230b32bca604","claim-603f0e998a28189ee7a8"],"holders":2}],"speakers":4,"view":"split"},"evidence_line":"26 statements from 4 speakers in 4 sources, all podcasts or videos","holder_line":"3 of the 4 named speakers in this finding take a side on this question: 2 on one side, 2 on the other, 1 on both; every named speaker in this finding is a confirmed clinician"},{"cited_clinicians":2,"id":"F8","population":"beyond","structure":{"claims":13,"claims_by_group":{"comparisons":1,"experience":3,"questions":3,"restated":1,"views":5},"limitations":4,"links":{"context":2,"support":14},"ma_question":true,"named_voices":2,"passages":8,"sources":2,"sources_by_kind":{"media":2}},"title":"Transplant deferral: how clinicians weigh MRD, disease risk and fitness","title_holders":{"cited_claim_ids":["claim-a2f9cf57d7c23bf5e029","claim-77dbe8dbf797aacc087a","claim-babffb2c9cb20170d898","claim-b3090ff092749099463a","claim-94acc5dc13d1eeee1a2f","claim-d92ab40ede114ec82944","claim-59c3d5064be3981fa9fc","claim-409fd4c2dd9f00b8e1ed","claim-6b6fd5fb2166fd45bd06"],"clinicians":true,"holders":2,"sides":[{"cited_claim_ids":["claim-a2f9cf57d7c23bf5e029","claim-77dbe8dbf797aacc087a","claim-babffb2c9cb20170d898","claim-b3090ff092749099463a","claim-94acc5dc13d1eeee1a2f","claim-d92ab40ede114ec82944"],"holders":1},{"cited_claim_ids":["claim-babffb2c9cb20170d898","claim-59c3d5064be3981fa9fc","claim-409fd4c2dd9f00b8e1ed","claim-6b6fd5fb2166fd45bd06"],"holders":1}],"speakers":2,"view":"split"},"evidence_line":"13 statements from 2 speakers in 2 sources, all podcasts or videos","holder_line":"2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other; every named speaker in this finding is a confirmed clinician"},{"cited_clinicians":3,"id":"F9","population":"beyond","structure":{"claims":27,"claims_by_group":{"comparisons":3,"experience":1,"questions":1,"restated":3,"views":19},"limitations":3,"links":{"context":1,"support":28},"ma_question":true,"named_voices":3,"passages":18,"sources":4,"sources_by_kind":{"media":4}},"title":"Frontline quadruplets: most clinicians favor use, but one flags uneven uptake","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-a514294e0b1178da739c","claim-08a6376e3e4320d1050b"],"clause":"one flags uneven uptake","holders":1},"cited_claim_ids":["claim-90c888e5058e5c5c6fdc","claim-fd5b10326728b292a578","claim-6bb2fe57f70557979b83","claim-7e231790281493c0a517","claim-70a67735f1d468a6b3c9","claim-da82e6c810ab93b2b3fa","claim-aef6a70cce68a0ba6113","claim-c5a304fdac5e8bcfd775","claim-3b84537dae8613311242"],"clinicians":true,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"27 statements from 3 speakers in 4 sources, all podcasts or videos","holder_line":"2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one flags uneven uptake”"},{"cited_clinicians":3,"id":"F10","population":"beyond","structure":{"claims":22,"claims_by_group":{"comparisons":0,"experience":2,"questions":3,"restated":6,"views":11},"limitations":4,"links":{"context":2,"support":23},"ma_question":true,"named_voices":3,"passages":12,"sources":3,"sources_by_kind":{"media":3}},"title":"Quadruplets in older age: why most clinicians favor selected use with dose adjustments","title_holders":{"cited_claim_ids":["claim-4bc2d476ef5f577677ca","claim-951bf77d2c16b59144f6","claim-017d4429654e5a86ea91","claim-3682a1009d235a62fbb0","claim-cfb4c046dca365832e32","claim-a35bcdddb66880180d75","claim-b8f83ba89eace5361a66","claim-c5a304fdac5e8bcfd775"],"clinicians":true,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"22 statements from 3 speakers in 3 sources, all podcasts or videos","holder_line":"2 of the 3 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":2,"id":"F11","population":"beyond","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":7},"limitations":3,"links":{"context":2,"support":10},"ma_question":true,"named_voices":3,"passages":6,"sources":2,"sources_by_kind":{"media":2}},"title":"Early dexamethasone stopping: a clinician sees a future template, not a universal rule","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-2055adc9a69493e2c1ee","claim-8ed4744811d4f94a6842"],"clause":"not a universal rule","holders":1},"cited_claim_ids":["claim-2055adc9a69493e2c1ee","claim-8ed4744811d4f94a6842"],"clinicians":true,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"9 statements from 3 speakers in 2 sources, all podcasts or videos","holder_line":"1 of the 3 named speakers in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “not a universal rule”"},{"cited_clinicians":2,"id":"F12","population":"beyond","structure":{"claims":18,"claims_by_group":{"comparisons":1,"experience":3,"questions":2,"restated":2,"views":10},"limitations":4,"links":{"context":3,"support":19},"ma_question":true,"named_voices":2,"passages":15,"sources":2,"sources_by_kind":{"media":2}},"title":"Carfilzomib: how a clinician weighs neuropathy, disease risk, access and cardiac risk","title_holders":{"cited_claim_ids":["claim-c970635d94ca28bef39e","claim-7262dd835a19a58c31fc","claim-3b60f841d7df31b97345","claim-52d64e01a389b3d80df8","claim-e63160d3db9677d9d321","claim-fd05fc8ea3be34e5fef5","claim-bfe699e26e4a02f4894b","claim-93d4e562919c895f3e04","claim-b17bf05721f108e882af","claim-d9c1c000c0903a7b90c7","claim-2759f7c589fec7b9ada3"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"18 statements from 2 speakers in 2 sources, all podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F13","population":"beyond","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":4,"questions":0,"restated":0,"views":2},"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Lenalidomide: a clinician favors early use but awaits stable renal function","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-3f7c19d83fead486086e","claim-cae89f20645cc24fc824"],"clause":"await stable renal function","holders":1},"cited_claim_ids":["claim-cae89f20645cc24fc824"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"6 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of the 1 holds its caveat, “await stable renal function”"},{"cited_clinicians":2,"id":"F14","population":"beyond","structure":{"claims":14,"claims_by_group":{"comparisons":3,"experience":3,"questions":2,"restated":0,"views":6},"limitations":4,"links":{"context":1,"support":14},"ma_question":true,"named_voices":2,"passages":9,"sources":3,"sources_by_kind":{"media":3}},"title":"CD38 antibodies: how clinicians weigh dosing and delivery experience","title_holders":{"cited_claim_ids":["claim-99ae289dc7d820e88227","claim-dfeb45ae61cbcdf6ddd6","claim-088db0cee38ea059c9ef","claim-7ff6f3636d4a11cfe00b","claim-e6b03e80d2652e9165bf","claim-b256b974fcca9526ab08","claim-af9272d5bcee37b56027","claim-37c2fd4b00ddaf0ce6b5","claim-8bb0b07aa8139324c11c"],"clinicians":true,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"14 statements from 2 speakers in 3 sources, all podcasts or videos","holder_line":"2 of the 2 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":2,"id":"F15","population":"beyond","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":0,"views":13},"limitations":5,"links":{"context":0,"support":18},"ma_question":true,"named_voices":2,"passages":9,"sources":2,"sources_by_kind":{"media":2}},"title":"CD38 care: a clinician stresses prevention; one plans for long-term therapy","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-9b90e879c46895f17541"],"clause":"one plans for long-term therapy","holders":1},"cited_claim_ids":["claim-fb0295ca166df98e558a","claim-ae7cbdddf7e92741ef51","claim-939b8e181a3d939e3b8a","claim-ac9a54698fd9d00a80e5","claim-31abe9217940f42055eb","claim-20efc7b311f76a12c075","claim-173a4fd525086d2203d3","claim-e4a7772018f7d51f2001","claim-819493bdaaa19212b9d4","claim-33850f2940585156c424"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"16 statements from 2 speakers in 2 sources, all podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “one plans for long-term therapy”"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One physician X account welcomes weekly KdD70; an organizational account shares its convenience rationale"},{"id":"section-2","level":2,"title":"One physician X account says treatment history matters when considering D-Pd or Isa-Pd"},{"id":"section-3","level":2,"title":"One physician X account welcomes D-Kd approval while hoping for future regional access"},{"id":"section-4","level":1,"title":"Beyond the trial population"},{"id":"section-5","level":2,"title":"One speaker explicitly prefers retaining daratumumab rather than lenalidomide when maintenance is reduced"},{"id":"section-6","level":2,"title":"Speakers distinguish favorable maintenance interpretations from uncertainty about its independent contribution"},{"id":"section-7","level":2,"title":"Speakers see promise in MRD-informed treatment reduction but keep stopping decisions conditional"},{"id":"section-8","level":2,"title":"Speakers retain transplantation while questioning when MRD or functional recovery could justify deferral"},{"id":"section-9","level":2,"title":"Speakers strongly favor contemporary frontline quadruplets, while one highlights uneven implementation"},{"id":"section-10","level":2,"title":"Speakers support selected older patients receiving quadruplets, with attenuation rather than unchanged intensity"},{"id":"section-11","level":2,"title":"One speaker sees early dexamethasone cessation as a potential template, not a universal current rule"},{"id":"section-12","level":2,"title":"One speaker favors carfilzomib for neuropathy or high-risk intensity, but preserves access and cardiac qualifications"},{"id":"section-13","level":2,"title":"One speaker favors early lenalidomide but would wait when creatinine clearance fluctuates"},{"id":"section-14","level":2,"title":"One discussion describes the antibodies as similar rather than interchangeable and weighs delivery experience"},{"id":"section-15","level":2,"title":"One speaker emphasizes preventive care; another emphasizes preparation for prolonged treatment"},{"id":"section-16","level":2,"title":"One patient asks whether potential benefit over D-Vd offsets Blenrep's vision risks"},{"id":"section-17","level":2,"title":"Scope and coverage of the reviewed discussion"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase1","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2}],"id":"T1","label":"Primary endpoint: Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)"},{"findings":[],"id":"T2","label":"Primary endpoint: Number of participants affected by dose-limiting toxicities"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-18T17:09:40.120530Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-18T17:27:36Z","record_hash":"e950ffc8424bcf6f00a75794fe9cf93f722271627b735972511ab3c480ff7e8b","release_hash":"374c6994c036abcabe3cb997b08067da524e4e06d5d8b13016d2d1ea6299b1de","report_id":"erudio-nct01998971","run_id":"0d1fe0b0-8021-4a73-8498-c118fe520110","schema_version":"5.0","slug":"equuleus-nct01998971","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A physician supports weekly D-Kd in EQUULEUS while relaying a cross-study comparison suggesting similar benefit and safety; this does not establish schedule equivalence. A medical oncologist considers prior treatment and refractoriness relevant to D-Pd/Isa-Pd selection but offers no sequencing rule. Direct commentary on the trial is brief; broader discussion of frontline anti-CD38 combinations and maintenance provides context rather than evidence of this trial’s outcomes.","examples":[],"meta_description":"34 sources screened · 244 verified statements (93 from clinicians verified by NPI or staff page) from 15 sources · 15 findings. Updated Nov 18, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-18T17:27:36Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-18T21:33:28Z","kind":"routine","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":34},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on adding daratumumab to pomalidomide and dexamethasone for relapsed or refractory multiple myeloma.","4 more clinician views in the sources used in this report are not yet captured as evidence in this edition.","98 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 41 sources about other trials or topics are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion. Organizational shares, patient perspectives, repeated material and unidentified speech cannot be counted as independent clinician agreement.","Some detailed discussion of MRD-adapted transplantation, ISKIA efficacy and tolerability, preferred MRD thresholds and endpoint recommendations could not be fully assessed, limiting completeness of those sections.","Full text was unavailable for the initial D-Pd and D-Kd results publications; their available abstracts and later publications provide context but not a complete account of the original reports.","A separate protocol was not available, and regulatory material was only partially reviewed. Time-specific approval and access statements are reported as expressed, not as current regulatory guidance.","Many contextual recordings do not name EQUULEUS and concern combinations or treatment phases it did not test. Their relevance to the clinical question does not make them trial results or validate extrapolation to all EQUULEUS cohorts.","Survey methods, denominators and representativeness were not sufficiently described to convert reported practice variation into prevalence estimates.","Several numerical descriptions were inconsistent or speculative. They are preserved as attributed interpretations or unresolved wording rather than corrected into clinical facts."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":6,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":9,"context":3,"results":3},"count":15,"evidence_window":{"end":"2025-08-06","start":"2017-12-04"},"retrieval_snapshot":"2026-11-18T06:46:21.752638Z","timeline":[{"count":1,"week":"2017-W49"},{"count":1,"week":"2020-W34"},{"count":1,"week":"2020-W44"},{"count":1,"week":"2020-W45"},{"count":1,"week":"2024-W13"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W32"}],"undated_sources":6},"quote_policies":[{"id":"clinicaltrials:NCT01998971:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT01998971:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:28637662","quote_policy":"short_quote_link_out"},{"id":"pubmed:31113777","quote_policy":"short_quote_link_out"},{"id":"pubmed:32078124","quote_policy":"short_quote_link_out"},{"id":"pubmed:33112184","quote_policy":"short_quote_link_out"},{"id":"pubmed:35876974","quote_policy":"short_quote_link_out"},{"id":"pubmed:36882409","quote_policy":"short_quote_link_out"},{"id":"openfda:a4d0efe9-5e54-467e-9eb4-56fa7d53b60b:20261110","quote_policy":"short_quote_link_out"},{"id":"openfda:1521d321-e724-4ffc-adad-34bf4f44fac7:20250828","quote_policy":"short_quote_link_out"},{"id":"openfda:b8c3b7f3-7e72-47af-be23-133e7bb3db59:20261006","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1095578383134744576:70c6dffa-2a32-435c-b293-e89d20fdc582","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1271074153660112897:bb39542a-f50a-4681-9ff7-7a83dcca31e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1291007295682469888:5d14de62-bd65-4829-8e18-e2ad79e9d645","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1296637178907426817:ca841a2a-5ea3-4e21-9eec-47a917a286cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1297904414989189120:715ec457-f09d-4663-a81e-4c2d686d3c5d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1297934368753819649:ea50d792-d8bc-40be-8930-d64c9fbcb23b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1298228631211315202:f002616f-cbca-4006-9d0a-d687b244c074","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1322075916714082305:bc373abb-a478-4429-b969-0d8876de8955","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1323637169886502912:6c88709f-2720-4cff-be3a-e91e7bf90c19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1368050711251083269:ffe5d3e6-50a9-4482-aa34-598c45ec438b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1519304182230134786:576fa0d5-6ea5-4282-937d-b1ea71d1d745","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533225246576222208:912c4ea2-4d89-40f0-9f87-aa806cb84509","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1535304359973625856:ae031235-f4de-46e6-9dd4-d73789b3ccb5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1633970115875094530:265a636e-7a93-4193-9678-85555c55057b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1640215829018017793:62afb48a-bfc2-45ee-b741-93fe0c4dbb54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1640221804319866880:9c35625c-824e-447d-8ed5-b04d8052a5bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1643283787667628035:2a33768a-c596-4058-8f79-9adf6bc90f90","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1669401391691907078:9d1e8a0b-f899-4fad-a266-0fdc39d4d9c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1695466659148874168:8c11161e-60bf-4b8d-b8c6-0a58d53d1755","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1759604253834854413:8c8b76fd-7d59-4746-b98b-821f1443e277","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1761061200660439361:08aeb6d0-3fd6-414b-9b64-d7cebb4fda4b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1773041899420406000:13b8d8ba-7a8f-4cde-9ec2-4063abfc6df2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:731076037199708160:89502839-fdd3-4984-ad7d-9287f9edc370","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:809129708071874560:7d5b8412-82c1-45c4-acd7-26032ee1f729","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:816844980677439488:dd41c1e5-e547-481b-983c-81260d904132","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:816905544300720128:dd7a85e0-a62e-4840-9ecf-ff8c029491c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:871574249642774528:00d97b06-28ca-405e-a903-c712c5dbe00b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:937568298345971714:72b6001f-76cd-49e6-9b80-54ab8210f611","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:3QqaBFRWkCk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:P8bknPBiqOI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Qk77c51HLp8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:aTaa1qeF0oA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:gx6RZ5JUu8c","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:pSC_Aus1GDY","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":28,"x_video":0,"youtube":6},"by_evidence_role":{"commentary":34},"count":34,"evidence_window":{"end":"2025-08-06","start":"2016-05-13"},"retrieval_snapshot":"2026-11-18T06:46:22.315955Z","timeline":[{"count":1,"week":"2016-W19"},{"count":1,"week":"2016-W50"},{"count":2,"week":"2017-W01"},{"count":1,"week":"2017-W23"},{"count":1,"week":"2017-W49"},{"count":1,"week":"2019-W07"},{"count":1,"week":"2020-W24"},{"count":1,"week":"2020-W32"},{"count":1,"week":"2020-W34"},{"count":3,"week":"2020-W35"},{"count":1,"week":"2020-W44"},{"count":1,"week":"2020-W45"},{"count":1,"week":"2021-W09"},{"count":1,"week":"2022-W17"},{"count":1,"week":"2022-W21"},{"count":1,"week":"2022-W22"},{"count":2,"week":"2022-W23"},{"count":1,"week":"2023-W10"},{"count":2,"week":"2023-W13"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W24"},{"count":1,"week":"2023-W34"},{"count":2,"week":"2024-W08"},{"count":1,"week":"2024-W13"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W30"},{"count":1,"week":"2025-W32"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":64,"registry":0,"regulatory":0,"x_thread":7,"x_video":0,"youtube":173}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Darzalex"],"label":"daratumumab","slug":"daratumumab"},{"brand_names":["Velcade"],"label":"bortezomib","slug":"bortezomib"},{"brand_names":["Pomalyst"],"label":"pomalidomide","slug":"pomalidomide"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"},{"brand_names":["Alkeran","Evomela","Ivra"],"label":"melphalan","slug":"melphalan"},{"brand_names":["Cortan","Delta-Dome","Deltasone","Fernisone","Liquid Pred","Meticorten","Orasone","Paracort","Prednicen-M","Rayos","Servisone"],"label":"prednisone","slug":"prednisone"},{"brand_names":["Thalomid"],"label":"thalidomide","slug":"thalidomide"},{"brand_names":["Antitussive","Beldin","Belix","Benadryl","Benadryl Preservative Free","Benylin","Dibenil","Diphen","Diphenhydramine Hcl","Hydramine","Silphen","Vicks Formula"],"label":"diphenhydramine","slug":"diphenhydramine"},{"brand_names":["8 Hour Pain Relief","8 Hr Muscle Aches And Pain","8Hr Arthritis Pain","8Hr Arthritis Pain Relief","8Hr Muscle Aches And Pain","8Hr Muscle Aches And Pain Relief","Amazon Basic Care Acetaminophen","Arthritis Pain","Arthritis Pain Relief","Equate 8Hr Arthritis Pain Relief","Good Sense Pain Relief Arthritis Pain","Injectapap","Leader 8Hr Arthritis Pain Relief","Ofirmev","Topcarehour Pain Relief","Topcarehr Arthritis Pain Relief","Tylenolhr Arthritis Pain","Tylenolhr Muscle Aches And Pain"],"label":"acetaminophen","slug":"acetaminophen"},{"brand_names":["Kyprolis"],"label":"carfilzomib","slug":"carfilzomib"},{"brand_names":["Revlimid"],"label":"lenalidomide","slug":"lenalidomide"},{"brand_names":["Singulair"],"label":"montelukast","slug":"montelukast"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"EQUULEUS","aliases":["EQUULEUS","CR103015","A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma"],"brief_title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Multiple Myeloma"],"display_condition":"multiple myeloma","display_interventions":[["daratumumab","carfilzomib","dexamethasone"],["daratumumab","pomalidomide","dexamethasone"],["daratumumab","carfilzomib","lenalidomide","dexamethasone"]],"enrollment":{"count":240,"type":"ACTUAL"},"interventions":[{"name":"Daratumumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Velcade","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pomalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Melphalan","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Prednisone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Thalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Diphenhydramine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Acetaminophen","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carfilzomib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Lenalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Montelukast","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT01998971","official_title":"An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma","overall_status":"COMPLETED","phase":["PHASE1"],"primary_completion_date":{"date":"2019-01-31","type":"ACTUAL"},"primary_endpoints":[{"measure":"Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)","timeFrame":"Up to 30 days after the last dose of study medication"},{"measure":"Number of participants affected by dose-limiting toxicities","timeFrame":"Up to 30 days after the last dose of study medication"}],"registered_date":{"date":"2013-12-03","type":"ESTIMATED"},"registry_last_updated":"2025-04-25","registry_url":"https://clinicaltrials.gov/study/NCT01998971","short_name":"EQUULEUS","short_name_basis":"canonical_name","sponsor":"Janssen Research & Development, LLC","start_date":{"date":"2014-02-18","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase1","study_ids":[{"id":"CR103015","type":"sponsor_study_id"},{"domain":"Janssen Research & Development, LLC","id":"54767414MMY1001","type":"other"},{"id":"2013-003491-12","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}